The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Gene: TLR3 | UniProt: O15455 | Organism: Homo sapiens (Human) | Chromosome: 4q35.1
Toll-like receptor 3 (TLR3) is a critical pattern-recognition receptor in the innate immune system that detects viral double-stranded RNA (dsRNA) and initiates antiviral and inflammatory responses. This report synthesizes current understanding of TLR3 function, structure, signaling mechanisms, and therapeutic applications, with emphasis on recent 2023-2025 discoveries. TLR3 represents a "double-edged sword" in immunity: essential for antiviral defense but potentially pathological when dysregulated (hsieh2025tolllikereceptor3 pages 1-2).
TLR3 functions as an intracellular pattern-recognition receptor whose primary role is detecting viral or damage-associated double-stranded RNA and converting this recognition into coordinated innate immune responses (han2023thefunctionalmechanisms pages 1-2, han2023thefunctionalmechanisms pages 3-5, ouattara2025tolllikereceptor3 pages 1-2). Unlike other pattern-recognition receptors that detect lipopolysaccharide, flagellin, or unmethylated CpG DNA, TLR3 exhibits specific substrate recognition for dsRNA, distinguishing it from single-stranded RNA sensors like TLR7 and TLR8 (han2023thefunctionalmechanisms pages 2-3, luan2024innateimmuneresponses pages 5-7).
Substrate Specificity:
TLR3 recognizes viral dsRNA with defined structural requirements rather than sequence-specific recognition (han2023thefunctionalmechanisms pages 2-3). The receptor binds dsRNA through its leucine-rich repeat (LRR) ectodomain, which contacts the ribose-phosphate backbone in the minor grooves of the RNA helix (sakaniwa2023tlr3formsa pages 1-2, han2023thefunctionalmechanisms pages 2-3). While a minimum of approximately 40-50 base pairs of dsRNA can form a stable complex with dimeric TLR3, robust cellular activation requires substantially longer dsRNA—generally at least 90 base pairs (luan2024innateimmuneresponses pages 5-7, hsieh2025tolllikereceptor3 pages 1-2). This length dependence reflects the importance of cooperative higher-order receptor assembly along extended RNA molecules for efficient signal transduction (sakaniwa2023tlr3formsa pages 3-4, sakaniwa2023tlr3formsa pages 1-2).
TLR3 recognizes multiple dsRNA sources: viral genomic RNA and replication intermediates from RNA viruses; synthetic dsRNA mimics including polyinosinic:polycytidylic acid [poly(I:C)], poly(A:U), and related agonists; and endogenous RNA released during tissue damage, including U1 RNA and structured single-stranded RNAs containing partial stem-loop configurations (ouattara2025tolllikereceptor3 pages 2-3, chai2025myd88contributesto pages 10-12, ouattara2025tolllikereceptor3 pages 1-2).
TLR3 is primarily localized to endosomal and lysosomal compartments, where the acidic environment (pH ≤ 6.5) supports efficient dsRNA binding (ouattara2025tolllikereceptor3 pages 2-3, ouattara2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 1-2). This endosomal positioning is consistent with its role as an intracellular sensor that monitors RNA internalized via endocytosis, autophagy, or viral entry (han2023thefunctionalmechanisms pages 2-3). In dendritic cells, TLR3 localizes to the endoplasmic reticulum and lysosomal membranes, with UNC93B1 chaperone protein supporting proper folding, trafficking, and endolysosomal delivery (han2023thefunctionalmechanisms pages 2-3, han2023thefunctionalmechanisms pages 1-2).
Cell-type-specific expression patterns expand TLR3's functional range: the receptor is present on the plasma membrane of fibroblasts and some epithelial cells, enabling detection of extracellular dsRNA (shrestha2024differentialtlrerk12activity pages 5-7, wang2025emergingrolesof pages 4-6, han2023thefunctionalmechanisms pages 2-3). This surface expression may facilitate rapid responses to viral infection or tissue damage at epithelial barriers. TLR3 is expressed not only in immune cells, including dendritic cells, macrophages, and natural killer cells, but also in epithelial cells, fibroblasts, endothelial cells, and neurons, reflecting its broad role in tissue-level pathogen defense and inflammation (hsieh2025tolllikereceptor3 pages 1-2).
A landmark 2023 cryo-electron microscopy study revealed that TLR3 forms laterally aligned multimeric complexes along long dsRNA for efficient signal transduction (sakaniwa2023tlr3formsa pages 3-4, sakaniwa2023tlr3formsa pages 1-2). While previous models established that dsRNA induces TLR3 dimerization, this work demonstrated that preformed dimers can assemble into higher-order tetrameric, hexameric, and octameric complexes through electrostatic interactions between charged surfaces at the N- and C-terminal regions of adjacent receptor units (sakaniwa2023tlr3formsa pages 3-4, sakaniwa2023tlr3formsa pages 1-2). This lateral multimerization mechanism explains why longer dsRNA molecules (≥90 bp) produce more robust signaling than the minimal 40-50 bp required for basic dimerization: extended RNA scaffolds support cooperative receptor clustering that amplifies downstream signaling (sakaniwa2023tlr3formsa pages 1-2, luan2024innateimmuneresponses pages 5-7).
Mutagenesis studies confirmed that disrupting the electrostatic dimer–dimer interface impairs signal transduction without preventing the initial RNA-induced dimerization step, establishing multimerization as a distinct and functionally important activation mechanism (sakaniwa2023tlr3formsa pages 3-4).
A paradigm-shifting 2025 study reported that MyD88, traditionally considered dispensable for TLR3 signaling, directly contributes to TLR3-mediated NF-κB activation and cytokine production in macrophages (chai2025myd88contributesto pages 12-14, chai2025myd88contributesto pages 10-12). Co-immunoprecipitation experiments demonstrated that activated TLR3 associates with MyD88 and induces MyD88 oligomerization in a TRIF-dependent manner (chai2025myd88contributesto pages 10-12). Functionally, MyD88-deficient macrophages exhibited reduced phosphorylation of NF-κB p65 and IκBα and diminished production of IL-6, TNF-α, and IFN-β following poly(I:C) stimulation (chai2025myd88contributesto pages 12-14).
This finding revises the traditional "exclusively TRIF-dependent" model of TLR3 signaling. TRIF remains essential—its absence abolishes TLR3 responsiveness—but MyD88 appears to provide an amplification branch that enhances NF-κB signaling dynamics and sustains cytokine production (chai2025myd88contributesto pages 12-14). These results expand the paradigm of TLR3 signaling by establishing MyD88 as a direct contributor, offering new insights into cross-talk between MyD88-dependent and -independent pathways.
Recent 2024-2025 studies identified TRIM56 as a critical positive regulator of TLR3-TRIF signaling through a non-canonical, E3 ligase-independent mechanism (liu2024keyrolesfor pages 11-12, wang2025emergingrolesof pages 4-6, liu2024keyrolesfor pages 1-2). TRIM56 interacts with TRIF early after TLR3 activation and enhances both IRF3 and NF-κB branches without affecting TRIF-independent pathways (liu2024keyrolesfor pages 11-12, liu2024keyrolesfor pages 1-2).
Domain mapping revealed that the entire coiled-coil domain and C-terminal regions (residues 434-610) are required for TLR3 potentiation, suggesting a scaffolding function that organizes signaling complexes (liu2024keyrolesfor pages 11-12, liu2024keyrolesfor pages 1-2). Critically, three phosphorylation sites—Ser471, Ser475, and Ser710—are essential: alanine substitution at any site eliminates TRIM56-mediated enhancement of TLR3 responses (liu2024keyrolesfor pages 11-12, liu2024keyrolesfor pages 1-2). Ser471 and Ser475 undergo biphasic phosphorylation with an early wave at 0.5-1 hour after TLR3 engagement, preceding TRIM56-TRIF association and IRF3 phosphorylation (liu2024keyrolesfor pages 11-12, wang2025emergingrolesof pages 4-6). Ser710 phosphorylation is specifically required for TRIM56 association with TRIF (liu2024keyrolesfor pages 11-12, manik2025structuralbasisfor pages 5-6).
A 2025 structural biology study elucidated the regulatory role of tyrosine phosphorylation in TLR3 activation (manik2025structuralbasisfor pages 5-6). TLR3 requires ligand-induced phosphorylation of Tyr759 and Tyr858 by tyrosine kinases including EGFR, Src, and Bruton's tyrosine kinase for TRIF recruitment (manik2025structuralbasisfor pages 5-6). Additionally, TRIF itself is regulated by time-dependent ubiquitination: K27-linked polyubiquitination of Lys523 by the cullin-3-Rbx1-KCTD10 E3 ligase complex initiates TLR3/TLR4 signaling within 10-15 minutes, while USP19-mediated deubiquitination after 40-60 minutes contributes to signal termination (manik2025structuralbasisfor pages 5-6).
TLR3 is a 904-amino-acid, ~103.8 kDa type I integral membrane glycoprotein encoded on chromosome 4q35.1 (ouattara2025tolllikereceptor3 pages 1-2, han2023thefunctionalmechanisms pages 1-2). The protein comprises three principal structural domains organized for sequential ligand recognition, membrane anchoring, and signal transduction:
| Domain/Region | Location (amino acid residues if available) | Structure | Function |
|---|---|---|---|
| Overall protein and gene | Full-length precursor: 904 amino acids; encoded by TLR3 on chromosome 4q35.1 | Type I, single-pass integral membrane glycoprotein; predicted molecular mass approximately 103.8 kDa. The gene spans about 19.2 kb, contains five exons, and has coding sequence distributed across exons 2–5. (ouattara2025tolllikereceptor3 pages 1-2, han2023thefunctionalmechanisms pages 1-2) | Endosomal pattern-recognition receptor that converts detection of double-stranded RNA (dsRNA) into antiviral, inflammatory, and context-dependent cell-death signaling. (han2023thefunctionalmechanisms pages 3-5, hu2024trifdependentsignalingand pages 1-2) |
| N-terminal signal peptide / precursor segment | N terminus; precise residue boundary not specified in the cited evidence | Cleavable targeting sequence consistent with UniProt’s designation of TLR3 as a precursor and with entry into the secretory pathway | Directs synthesis and membrane insertion through the endoplasmic reticulum, enabling maturation and trafficking to endosomal or lysosomal membranes; this targeting role is inferred from the type I membrane topology and intracellular localization. (han2023thefunctionalmechanisms pages 1-2) |
| Extracellular/luminal ectodomain (ECD) | Large N-terminal region preceding the transmembrane helix; exact boundaries not specified here | Curved solenoid containing the leucine-rich-repeat region; situated in the endosomal lumen in the receptor’s principal functional location. (ouattara2025tolllikereceptor3 pages 1-2, han2023thefunctionalmechanisms pages 2-3) | Recognizes dsRNA in an acidic endosomal environment, preferentially at pH ≤6.5; binding is based mainly on RNA structure and backbone rather than nucleotide sequence. (han2023thefunctionalmechanisms pages 2-3, ouattara2025tolllikereceptor3 pages 1-2) |
| Leucine-rich-repeat domain (LRR1–LRR23) | N-terminal ectodomain; 23 LRR motifs | Horseshoe-shaped, right-handed curved solenoid with β-sheet and α-helical elements; includes binding surfaces near both the N- and C-terminal ends of the horseshoe. (ouattara2025tolllikereceptor3 pages 1-2, han2023thefunctionalmechanisms pages 2-3) | Provides the dsRNA-recognition surface. Two TLR3 ectodomains bind one dsRNA molecule and contact its ribose-phosphate backbone in minor grooves, explaining the receptor’s limited sequence specificity. (sakaniwa2023tlr3formsa pages 1-2, han2023thefunctionalmechanisms pages 2-3) |
| C-terminal LRR cap / cysteine-rich flank (LRR-CT; Cys-rich_flank_reg_C) | C-terminal end of the ectodomain, immediately before the membrane-proximal region; exact residues not specified | Cysteine-rich cap that terminates and stabilizes the LRR solenoid | Contributes to ectodomain integrity and the C-terminal dsRNA-binding/dimerization surface; helps position paired ectodomains in the signaling-competent complex. (han2023thefunctionalmechanisms pages 2-3) |
| dsRNA-binding and receptor-dimerization assembly | Distributed across N- and C-terminal surfaces of the LRR ectodomain | Approximately 40–50 bp of dsRNA, including a stable complex at about 46 bp, can support a basic TLR3 dimer. Longer dsRNA—generally ≥90 bp for robust cellular signaling—supports lateral association of multiple dimers into tetrameric and larger assemblies. (sakaniwa2023tlr3formsa pages 3-4, sakaniwa2023tlr3formsa pages 1-2, luan2024innateimmuneresponses pages 5-7) | Ligand-induced dimerization brings the intracellular signaling regions into proximity. Electrostatic dimer–dimer contacts produce cooperative higher-order assembly along long dsRNA, increasing signaling efficiency. (sakaniwa2023tlr3formsa pages 3-4, sakaniwa2023tlr3formsa pages 1-2) |
| Single-pass transmembrane domain | Between the luminal ectodomain and cytoplasmic tail; exact residue boundary not specified in the cited evidence | One α-helical membrane-spanning segment characteristic of a type I integral membrane receptor | Anchors TLR3 in endosomal, lysosomal, and—depending on cell type—plasma membranes; mechanically couples ligand-driven ectodomain assembly to organization of the cytoplasmic signaling domains. (ouattara2025tolllikereceptor3 pages 2-3, wang2025emergingrolesof pages 4-6, han2023thefunctionalmechanisms pages 2-3) |
| Cytoplasmic juxtamembrane/signaling region | Cytoplasmic region adjoining the transmembrane helix; includes functionally important Tyr759 according to the cited structural-signaling synthesis | Regulatory segment subject to ligand-induced tyrosine phosphorylation by kinases reported to include EGFR, Src, and BTK | Phosphorylation contributes to formation of a signaling-competent receptor and recruitment of the adaptor TRIF. (manik2025structuralbasisfor pages 5-6) |
| Toll/interleukin-1 receptor homology (TIR) domain | C-terminal cytoplasmic domain; includes functionally important Tyr858 according to the cited structural-signaling synthesis | Conserved TIR signaling fold; does not bind dsRNA directly | Directly recruits the TIR-containing adaptor TRIF/TICAM-1. TRIF then activates TBK1–IKKε–IRF3 signaling for type I interferon production and TRAF6/RIPK1–TAK1–IKK signaling for NF-κB-dependent inflammatory transcription; the pathway can also engage apoptosis or necroptosis. (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 2-3, manik2025structuralbasisfor pages 5-6) |
Table: This table maps the principal structural regions of human TLR3 (UniProt O15455) to their molecular architecture and functions. It highlights how the LRR ectodomain, transmembrane helix, and cytoplasmic TIR domain couple dsRNA recognition to TRIF-dependent signaling.
The extracellular leucine-rich repeat domain contains 23 LRR motifs arranged in a horseshoe-shaped solenoid structure (ouattara2025tolllikereceptor3 pages 1-2, han2023thefunctionalmechanisms pages 2-3). This architecture provides the dsRNA-binding surface, with binding sites positioned near both the N- and C-terminal ends of the horseshoe (han2023thefunctionalmechanisms pages 2-3). The transmembrane helix anchors the receptor in endosomal, lysosomal, and—in certain cell types—plasma membranes (ouattara2025tolllikereceptor3 pages 2-3, han2023thefunctionalmechanisms pages 2-3). The cytoplasmic TIR domain recruits the adaptor protein TRIF/TICAM-1, initiating downstream signaling cascades (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 1-2, manik2025structuralbasisfor pages 5-6).
TLR3 signals primarily through the adaptor TRIF (TIR-domain-containing adapter-inducing interferon-β, also called TICAM-1), which directly binds the TLR3 cytoplasmic TIR domain following receptor activation (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 2-3). This contrasts with most other TLRs, which signal through MyD88. TRIF orchestrates multiple downstream branches:
| Signaling Branch | Key Adaptor/Mediators | Downstream Effectors | Biological Outcome |
|---|---|---|---|
| Canonical interferon branch: TLR3–TRIF–TBK1–IRF3 | dsRNA-induced TLR3 dimerization brings cytoplasmic TIR domains together, enabling direct recruitment of TRIF/TICAM-1. TRIF recruits TRAF3, TBK1, IKKε, and NAP1. (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 2-3, luan2024innateimmuneresponses pages 5-7) | TBK1 and IKKε phosphorylate IRF3 and, contextually, IRF7; IRF dimers translocate to the nucleus and cooperate with NF-κB and ATF-2/c-Jun at interferon promoters. (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 2-3) | Induction of IFN-β and other type I interferons, followed by JAK–STAT-dependent interferon-stimulated genes and establishment of an antiviral state. (wang2025emergingrolesof pages 4-6, han2023thefunctionalmechanisms pages 3-5) |
| Inflammatory branch: TRIF–TRAF6–TAK1–NF-κB/AP-1 | The N-terminal region of TRIF recruits TRAF6; TRAF6 generates K63-linked polyubiquitin scaffolds that recruit the TAK1–TAB1/TAB2 complex. (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 2-3) | TAK1 activates the IKK complex (IKKα, IKKβ, and NEMO/IKKγ), causing IκBα phosphorylation and release of NF-κB p50/p65. TAK1 also activates MKK4/MKK7–JNK–AP-1 signaling. (han2023thefunctionalmechanisms pages 2-3, han2023thefunctionalmechanisms pages 3-5) | Transcription of inflammatory cytokines and chemokines, including context-dependent IL-6 and TNF-α, plus coordinated antiviral and immune-cell recruitment programs. (chai2025myd88contributesto pages 12-14, han2023thefunctionalmechanisms pages 3-5) |
| Alternative inflammatory branch: TRIF–RIPK1–TAK1–NF-κB | The C-terminal RHIM of TRIF binds the RHIM of RIPK1. RIPK1 polyubiquitination supports recruitment of TAK1–TAB2 and activation of the IKK machinery. (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 2-3, hu2024trifdependentsignalingand pages 5-6) | TAK1 activates the IKK complex, leading to IκB degradation and nuclear translocation of NF-κB. RIPK3 can compete for RHIM interactions and restrain RIPK1-dependent NF-κB signaling in some contexts. (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 5-6) | Reinforces inflammatory gene expression and provides a signaling junction at which TLR3 responses can shift between inflammation, apoptosis, and necroptosis. (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 5-6) |
| MyD88-dependent amplification—emerging 2025 model | Although TRIF remains indispensable, activated TLR3 was reported to associate with MyD88 and induce MyD88 oligomerization in macrophages; this oligomerization required TLR3 and was strongly dependent on TRIF. (chai2025myd88contributesto pages 10-12, chai2025myd88contributesto pages 12-14) | MyD88 contributes to phosphorylation of NF-κB p65 and IκBα and may sustain later TBK1 phosphorylation. Its absence reduces—but does not eliminate—TLR3 responses, whereas TRIF loss abolishes responsiveness. (chai2025myd88contributesto pages 12-14) | Amplification of NF-κB activity and production of IL-6, TNF-α, and IFN-β. This revises the traditional “exclusively TRIF-dependent” model, but presently rests mainly on mouse-macrophage evidence and requires broader validation. (chai2025myd88contributesto pages 12-14, chai2025myd88contributesto pages 10-12) |
| Positive regulation by TRIM56 | TRIM56 associates early with TRIF following TLR3 stimulation. Its coiled-coil domain and C-terminal residues 434–610 provide a signaling scaffold; this activity is independent of its RING E3-ligase function. (liu2024keyrolesfor pages 11-12, liu2024keyrolesfor pages 1-2) | Phosphorylation of TRIM56 Ser471, Ser475, and Ser710 is required for potentiation; Ser710 supports TRIF association. TRIM56 enhances both IRF3 and NF-κB branches without enhancing unrelated TNF-α or IL-1β pathways. (liu2024keyrolesfor pages 11-12, wang2025emergingrolesof pages 4-6) | Strengthens type I interferon, interferon-stimulated gene, chemokine, and antiviral-state induction specifically downstream of extracellular dsRNA–TLR3–TRIF signaling. (wang2025emergingrolesof pages 4-6, liu2024keyrolesfor pages 1-2) |
| TRIF–RIPK1–FADD–caspase-8 apoptosis | The TRIF RHIM engages RIPK1, which recruits FADD and promotes assembly of a death-inducing signaling complex. (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 5-6) | FADD promotes oligomerization and activation of caspase-8, followed by executioner-caspase signaling. (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 5-6) | Programmed apoptotic death of infected, stressed, or—in some settings—malignant cells; the magnitude and consequence depend on cell type and competing survival signals. (hu2024trifdependentsignalingand pages 1-2, han2023thefunctionalmechanisms pages 3-5) |
| TRIF–RIPK3–MLKL necroptosis | TRIF engages RIPK3 through RHIM-dependent interactions, particularly when caspase-8 activity is absent or inhibited. (hu2024trifdependentsignalingand pages 2-3, hu2024trifdependentsignalingand pages 5-6) | RIPK3 activation and autophosphorylation lead to phosphorylation and oligomerization of MLKL; activated MLKL translocates to and disrupts cellular membranes. (hu2024trifdependentsignalingand pages 5-6) | Lytic necroptotic cell death, release of inflammatory cellular contents, and potential amplification of host defense or pathological tissue injury. (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 5-6) |
Table: This table maps ligand-activated TLR3 to its canonical TRIF-dependent interferon and inflammatory pathways, regulated cell-death outputs, and newer MyD88 and TRIM56 regulatory findings. It distinguishes established pathway architecture from the emerging 2025 MyD88-amplification model.
Interferon Branch: TRIF recruits TRAF3, TBK1, IKKε, and NAP1 to form a signaling complex at its N-terminal region (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 2-3, han2023thefunctionalmechanisms pages 2-3). TBK1 and IKKε phosphorylate IRF3 and IRF7, enabling their dimerization and nuclear translocation (hu2024trifdependentsignalingand pages 3-5, han2023thefunctionalmechanisms pages 3-5). Nuclear IRF3 cooperates with NF-κB and ATF-2/c-Jun to drive transcription of type I interferons, particularly IFN-β, establishing an antiviral state and inducing interferon-stimulated genes (wang2025emergingrolesof pages 4-6, han2023thefunctionalmechanisms pages 3-5, hu2024trifdependentsignalingand pages 5-6).
Inflammatory/NF-κB Branch: TRIF activates NF-κB through two parallel mechanisms. The N-terminal TRAF6-binding motif recruits TRAF6, which generates K63-linked polyubiquitin chains that scaffold TAK1-TAB1/TAB2 complex assembly (hu2024trifdependentsignalingand pages 3-5, hu2024trifdependentsignalingand pages 2-3, han2023thefunctionalmechanisms pages 2-3). Activated TAK1 phosphorylates the IKK complex (IKKα, IKKβ, and NEMO/IKKγ), leading to IκBα phosphorylation and degradation, releasing NF-κB (p50/p65 heterodimer) for nuclear translocation (han2023thefunctionalmechanisms pages 2-3, han2023thefunctionalmechanisms pages 3-5). TAK1 also activates the MKK4/MKK7-JNK-AP-1 axis (han2023thefunctionalmechanisms pages 2-3, han2023thefunctionalmechanisms pages 3-5).
The C-terminal RHIM domain of TRIF binds RIPK1, whose polyubiquitination provides an alternative route to TAK1-TAB2 activation and NF-κB signaling (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 2-3, hu2024trifdependentsignalingand pages 5-6). RIPK3 can compete for RHIM interactions and modulate RIPK1-dependent NF-κB responses (hu2024trifdependentsignalingand pages 5-6).
Cell Death Pathways: TRIF can engage programmed cell death through two mechanisms. The TRIF-RIPK1-FADD pathway promotes caspase-8 oligomerization and apoptosis (hu2024trifdependentsignalingand pages 1-2, hu2024trifdependentsignalingand pages 5-6). Alternatively, TRIF-RIPK3 interactions lead to RIPK3 autophosphorylation, MLKL phosphorylation and oligomerization, membrane translocation, and necroptotic cell death, particularly when caspase-8 is inhibited (hu2024trifdependentsignalingand pages 2-3, hu2024trifdependentsignalingand pages 5-6).
TLR3 activation produces coordinated outputs: type I interferon production and interferon-stimulated gene expression establish an antiviral state; inflammatory cytokines including IL-6, TNF-α, and chemokines recruit and activate immune cells; apoptosis or necroptosis can eliminate infected or damaged cells; and dendritic cell maturation bridges innate and adaptive immunity (wang2025emergingrolesof pages 4-6, han2023thefunctionalmechanisms pages 3-5, hu2024trifdependentsignalingand pages 5-6).
TLR3 agonists are being investigated as cancer immunotherapeutics based on their ability to induce type I interferons, activate NK cells and cytotoxic T cells, promote dendritic cell maturation, and directly trigger tumor cell apoptosis (butkowsky2023toll‑likereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 4-6). Several synthetic dsRNA agonists are in clinical development:
| Disease/Application Category | Specific Conditions/Agents | Clinical Status/Evidence Level | Key Findings/Outcomes |
|---|---|---|---|
| Cancer immunotherapy—poly(I:C) | Breast, gastric, colorectal, oral squamous-cell, hepatocellular, and other cancers; combinations with paclitaxel, cisplatin, sorafenib, cetuximab, checkpoint blockade, or cancer vaccines | Primarily preclinical and early translational; 2023–2025 reviews describe investigational use rather than an approved standard therapy | Activates TLR3–TRIF signaling, type I interferons, dendritic-cell maturation, NK and CD8 T-cell responses, and sometimes tumor-cell apoptosis. Clinical translation is limited by heterogeneous molecular size, instability, short half-life, systemic inflammation, and toxicity; context-dependent protumor signaling is also possible. (han2023thefunctionalmechanisms pages 3-5, butkowsky2023toll‑likereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 2-4) |
| Cancer immunotherapy—poly A:U | Historical adjuvant therapy in breast and locally advanced gastric cancer; gastric regimens included 5-fluorouracil and doxorubicin | Evaluated in clinical studies, including adjuvant breast-cancer studies and a phase III gastric-cancer trial; evidence is historical and has not established routine contemporary use | Some studies reported improved relapse-free or overall survival and reduced recurrence, but the evidence has not produced broadly adopted TLR3-directed standard care. (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 4-6) |
| Cancer immunotherapy—rintatolimod (Ampligen) | Investigated with HER2/neu peptide vaccination and with IFN-α2b plus celecoxib | Clinical investigation/combination immunotherapy; no definitive efficacy or routine oncology approval established in the cited 2025 review | Designed to stimulate dsRNA-sensing immune pathways while improving the tolerability or formulation limitations of unmodified poly(I:C); current use remains investigational. (hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 4-6) |
| Cancer immunotherapy—poly ICLC (Hiltonol) | Glioblastoma with radiotherapy; head-and-neck cancer, melanoma, leukemia, and solid tumors; combinations with immune-checkpoint inhibitors or vaccines | Phase I–II experience and a phase II glioblastoma/radiation study are reported; additional trials were ongoing or under investigation in the 2025 review | Stabilized poly(I:C) derivative intended to enhance innate and adaptive antitumor immunity. Potential benefits must be balanced against systemic inflammatory toxicity, delivery constraints, and tumor-specific protumor effects. (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 4-6) |
| Cancer prognostic or predictive biomarker | Hepatocellular carcinoma, melanoma, non-small-cell lung cancer, neuroblastoma, colorectal, esophageal, gastric, breast, renal, oral squamous-cell, and prostate cancers | Observational tumor-expression and outcome studies; not a validated pan-cancer clinical biomarker | High TLR3 expression has correlated with favorable prognosis or immune-active tumors in several cancers, but with worse outcomes in oral squamous-cell and prostate cancers and mixed results elsewhere. Interpretation must account for tumor type, receptor localization, immune context, and treatment. (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 2-4) |
| Vaccine adjuvants | Poly(I:C), poly ICLC, poly A:U, and defined dsRNA agonists; infectious-disease and cancer vaccines | Preclinical development plus phase I–II evaluation of selected TLR3-agonist approaches; no general-purpose TLR3 adjuvant is established as routine care in the cited evidence | TLR3 agonism can promote dendritic-cell maturation, antigen presentation, Th1-skewed antibodies, NK-cell activity, and cytotoxic CD8 T-cell responses. Defined or targeted formulations aim to preserve adjuvanticity while reducing systemic cytokine toxicity. (chai2025myd88contributesto pages 17-17, butkowsky2023toll‑likereceptor3 pages 1-2) |
| Antiviral immunity—HBV and HCV | Hepatitis B and C; experimental stimulation with poly(I:C) | Mechanistic human association studies and preclinical/translational evidence; not an established antiviral treatment | TLR3 activation can induce type I/III interferons and suppress HBV replication. HCV proteins can impair the pathway by cleaving or downregulating TRIF, while TLR3 expression or variation may influence viral clearance, chronicity, fibrosis, cirrhosis, and hepatocellular carcinoma risk. (han2023thefunctionalmechanisms pages 6-7, ouattara2025tolllikereceptor3 pages 1-2) |
| Antiviral immunity—other viruses | Influenza A, SARS-CoV-2, HSV-1, chikungunya, Ebola, respiratory syncytial virus, rhinovirus, vaccinia, and West Nile virus | Predominantly experimental, observational, or preclinical evidence; effects differ by virus and tissue | TLR3-mediated interferon responses can restrict viral replication and support clearance, but excessive signaling can increase cytokine production, inflammatory-cell accumulation, viral-associated tissue injury, or mortality. Protective associations were reported for HSV-1, HBV, chikungunya, Ebola, and SARS-CoV-2, whereas detrimental effects occurred in some influenza, RSV, rhinovirus, vaccinia, and West Nile models. (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 7-9) |
| Autoimmune and inflammatory disease | Rheumatoid arthritis, lupus nephritis, type 1 diabetes, psoriasis, Sjögren’s syndrome, and celiac disease | Disease-association and mechanistic evidence; therapeutic targeting remains investigational | Endogenous or damage-associated RNA can drive TLR3-dependent type I interferon, NF-κB/IRF3, cytokine, chemokine, and immune-cell recruitment programs. Excessive activation may promote tissue injury, including epithelial or pancreatic β-cell apoptosis, but disease-specific causality and therapeutic windows remain unresolved. (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 9-10) |
| Allergic disease | Seasonal allergic rhinitis, asthma, atopic dermatitis, and contact dermatitis | Mechanistic and disease-association evidence; no established TLR3-directed standard therapy | Dysregulated TLR3 signaling has been linked to airway inflammation and obstruction, leukocyte and eosinophil recruitment, edema, and pruritus. Both antiviral protection and exacerbation of allergic inflammation are biologically plausible, making context-selective modulation necessary. (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 9-10) |
| Cardiovascular and calcific disease | Aortic stenosis/calcific aortic-valve disease; endogenous dsRNA-like or damage-associated signaling | Recent preclinical and human-genetic association evidence; pharmacological inhibition remains experimental | TLR3 can promote inflammatory and osteogenic programs in valvular cells. This expands therapeutic interest beyond agonism: inhibition may be useful where endogenous-RNA sensing drives chronic inflammation or tissue calcification, but clinical benefit is unproven. (han2023thefunctionalmechanisms pages 3-5, han2023thefunctionalmechanisms pages 2-3) |
| Overall translational assessment | Agonism for antiviral immunity, vaccines, and selected tumors; inhibition for inflammatory or tissue-injury states | No broadly accepted, routine TLR3-directed therapy is established by the cited 2023–2025 literature | Authoritative reviews characterize TLR3 as a “double-edged sword”: benefit depends on ligand formulation, dose, delivery route, receptor localization, cell type, tumor or pathogen context, and control of systemic inflammation. Biomarker-guided patient selection and localized delivery are major development priorities. (hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 1-2) |
Table: This table summarizes clinical and translational uses of TLR3 modulation alongside major disease associations. It distinguishes clinical studies from preclinical evidence and emphasizes the receptor’s context-dependent protective and pathological effects.
Poly(I:C) and derivatives have been evaluated in breast, gastric, colorectal, oral squamous cell, hepatocellular, and other cancers, often in combination with chemotherapy (paclitaxel, cisplatin, 5-fluorouracil), targeted therapy (sorafenib, cetuximab), or immune checkpoint inhibitors (han2023thefunctionalmechanisms pages 6-7, han2023thefunctionalmechanisms pages 3-5, butkowsky2023toll‑likereceptor3 pages 1-2). Poly A:U demonstrated improved overall and relapse-free survival in historical breast cancer adjuvant studies and prolonged survival when combined with chemotherapy in locally advanced gastric cancer (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 4-6). Rintatolimod (Ampligen) is being studied with HER2/neu peptide vaccines and IFN-α2b plus celecoxib combinations (hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 4-6). Poly ICLC (Hiltonol), a stabilized derivative, has shown promise in glioblastoma with radiotherapy, head-and-neck cancer, melanoma, and as an adjunct to checkpoint inhibitors (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 4-6).
However, clinical translation faces significant challenges: poly(I:C) has heterogeneous molecular size, poor stability, short half-life, and substantial systemic toxicity (han2023thefunctionalmechanisms pages 3-5, butkowsky2023toll‑likereceptor3 pages 1-2). Context-dependent protumor effects are also possible: TLR3 signaling can promote cancer stem cell phenotypes, chemoresistance, NF-κB-driven inflammation, invasion, angiogenesis, and metastasis in certain tumor contexts (hsieh2025tolllikereceptor3 pages 2-4). Nanoparticle delivery systems, PLGA microspheres, and liposomes are being explored to achieve targeted delivery and reduce systemic toxicity (han2023thefunctionalmechanisms pages 3-5).
TLR3 agonists are being developed as vaccine adjuvants because they promote dendritic cell maturation, enhance antigen presentation, skew toward Th1-type antibody responses, and activate CD8+ T cells (chai2025myd88contributesto pages 17-17, butkowsky2023toll‑likereceptor3 pages 1-2). Multiple TLR3-adjuvanted vaccine approaches have entered Phase I-II clinical trials for infectious diseases and cancer vaccines (butkowsky2023toll‑likereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 4-6). The challenge is preserving adjuvanticity while minimizing systemic cytokine-mediated toxicity through defined formulations, targeted delivery, or dose optimization (chai2025myd88contributesto pages 17-17).
TLR3 activation can suppress viral replication and promote viral clearance through interferon-dependent mechanisms. In hepatitis B virus (HBV) infection, poly(I:C) stimulation suppresses viral replication and promotes interferon-dependent clearance (han2023thefunctionalmechanisms pages 6-7, ouattara2025tolllikereceptor3 pages 1-2). In hepatitis C virus (HCV) infection, TLR3 expression and genetic variants influence viral clearance, chronicity, disease progression, and risk of fibrosis, cirrhosis, and hepatocellular carcinoma; however, HCV proteins can impair the pathway by cleaving or downregulating TRIF (ouattara2025tolllikereceptor3 pages 1-2).
Protective TLR3-mediated antiviral effects have been reported for chikungunya virus, Ebola virus, herpes simplex virus-1 (HSV-1), and SARS-CoV-2 (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 7-9). Conversely, excessive TLR3 activation can worsen outcomes in influenza A, respiratory syncytial virus, rhinovirus, vaccinia, and West Nile virus infections through increased inflammatory cytokine production, tissue injury, or inflammatory CD8+ T cell accumulation (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 7-9).
TLR3 expression has been investigated as a prognostic biomarker across multiple cancers with context-dependent associations (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 2-4). High TLR3 expression correlated with favorable prognosis, immune-active tumor microenvironments, reduced invasion, or increased apoptosis in hepatocellular carcinoma, melanoma, non-small cell lung cancer, neuroblastoma, colorectal, esophageal, and gastric cancers (han2023thefunctionalmechanisms pages 6-7, hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 2-4). Conversely, high expression associated with worse outcomes in oral squamous cell carcinoma and prostate cancer (hsieh2025tolllikereceptor3 pages 2-4). Interpretation must account for tumor type, receptor localization (membrane versus intracellular), immune context, and treatment regimen (han2023thefunctionalmechanisms pages 3-5, hsieh2025tolllikereceptor3 pages 12-12).
TLR3 plays critical but bidirectional roles in viral infections. Its dsRNA-sensing function can protect against infection by inducing interferons, activating immune cells, and restricting viral spread (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 7-9). However, excessive or dysregulated signaling may contribute to viral-associated pathology, tissue injury, and mortality, earning TLR3 the characterization as a "double-edged sword" (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 7-9).
TLR3 has been associated with rheumatoid arthritis, lupus nephritis, type 1 diabetes mellitus, psoriasis, Sjögren's syndrome, and celiac disease (hsieh2025tolllikereceptor3 pages 9-10, hsieh2025tolllikereceptor3 pages 7-9). Mechanisms include aberrant recognition of endogenous or damage-associated RNA, leading to type I interferon production, NF-κB/IRF3 signaling, cytokine and chemokine production, immune cell recruitment, and tissue injury including epithelial or pancreatic β-cell apoptosis (hsieh2025tolllikereceptor3 pages 9-10). Reduced anti-inflammatory IL-10 production may exacerbate inflammation (hsieh2025tolllikereceptor3 pages 9-10).
TLR3 has been linked to seasonal allergic rhinitis, asthma, atopic dermatitis, and contact dermatitis (hsieh2025tolllikereceptor3 pages 9-10). Dysregulated signaling contributes to airway inflammation, obstruction, leukocyte infiltration, eosinophil recruitment, edema, and pruritus (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 9-10).
Recent preclinical evidence and human genetic association studies implicate TLR3 in calcific aortic valve disease and aortic stenosis (han2023thefunctionalmechanisms pages 3-5, han2023thefunctionalmechanisms pages 2-3). TLR3 can promote inflammatory and osteogenic programs in valvular cells through endogenous dsRNA-like or damage-associated signaling, suggesting that TLR3 inhibition—rather than agonism—may have therapeutic potential in chronic inflammation or tissue calcification contexts (han2023thefunctionalmechanisms pages 3-5).
Leading authorities characterize TLR3 as a "double-edged sword" whose activation produces context-dependent protective and pathological effects (hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 1-2). A comprehensive 2025 review in Biomarker Research emphasizes that TLR3's dual role necessitates careful modulation to maximize protective immunity while minimizing harmful inflammation (hsieh2025tolllikereceptor3 pages 1-2). The authors note that TLR3 enhances anti-viral defenses and promotes pathogen clearance on one hand, but excessive or dysregulated signaling can lead to chronic inflammation and tissue damage, exacerbating autoimmune diseases, chronic viral infections, and cancer (hsieh2025tolllikereceptor3 pages 1-2).
In cancer, TLR3 expression has been linked to both favorable and poor prognoses, though the underlying mechanisms remain incompletely understood (hsieh2025tolllikereceptor3 pages 1-2, hsieh2025tolllikereceptor3 pages 2-4). Recent advances in TLR3 agonist development for cancer immunotherapy attempt to capitalize on the receptor's potential to enhance anti-tumor responses, but definitive clinical efficacy has not been established (hsieh2025tolllikereceptor3 pages 12-12, hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 4-6).
The field consensus is that therapeutic success requires biomarker-guided patient selection, optimized formulations (defined structure, improved stability, controlled release), targeted delivery to minimize systemic inflammation, and careful consideration of tumor type, receptor localization, immune context, and dose (han2023thefunctionalmechanisms pages 3-5, hsieh2025tolllikereceptor3 pages 2-4, hsieh2025tolllikereceptor3 pages 1-2).
TLR3 is a critical pattern-recognition receptor that detects viral and damage-associated double-stranded RNA and orchestrates antiviral, inflammatory, and cell death responses through TRIF-dependent signaling. Recent 2023-2025 discoveries have revealed sophisticated mechanisms of TLR3 activation through lateral receptor multimerization along extended dsRNA, a previously unrecognized MyD88-dependent amplification branch, and phosphorylation-dependent regulation by TRIM56.
TLR3 represents an active area of translational research with investigational applications in cancer immunotherapy, vaccine development, and antiviral therapy. Multiple synthetic agonists are in clinical development, though no TLR3-directed therapy is currently approved for routine use. The receptor's context-dependent dual role—protective in antiviral immunity but potentially pathological in chronic inflammation, autoimmunity, and certain cancers—requires careful therapeutic targeting.
Future research priorities include structural biology of full-length receptor assemblies, elucidation of cell-type-specific regulatory mechanisms, development of targeted delivery systems, identification of predictive biomarkers, and rigorous clinical validation of TLR3-directed interventions.
This report synthesizes evidence from 62 pieces of evidence drawn from 12 relevant peer-reviewed papers published between 2023-2025, including publications in Nature Communications (highest quality peer-reviewed), Biomarker Research, Frontiers in Immunology, Journal of Biological Chemistry, Cells, Viruses, Proceedings of the National Academy of Sciences, and other authoritative journals. All major claims are supported by specific citations to primary literature as indicated throughout the text ( format).
Key Recent Publications (2023-2025):
- Sakaniwa et al. (2023). Nature Communications - Structural mechanisms of lateral TLR3 multimerization
- Chai et al. (2025). Cells - MyD88 contribution to TLR3 signaling
- Liu et al. (2024). Journal of Biological Chemistry - TRIM56 phosphorylation and TLR3 regulation
- Hsieh et al. (2025). Biomarker Research - TLR3 as a double-edged sword review
- Manik et al. (2025). PNAS - Structural basis of TRIF/TRAM signaling
- Wang & Li (2025). Viruses - Emerging roles of TRIM56 in antiviral immunity
Report generated with comprehensive literature analysis prioritizing recent 2023-2025 authoritative sources and primary research evidence.
References
(hsieh2025tolllikereceptor3 pages 1-2): Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, and Razelle Kurzrock. Toll-like receptor 3: a double-edged sword. Biomarker Research, Feb 2025. URL: https://doi.org/10.1186/s40364-025-00739-5, doi:10.1186/s40364-025-00739-5. This article has 46 citations and is from a peer-reviewed journal.
(han2023thefunctionalmechanisms pages 1-2): Bin Han, Chao Zhang, Xiaoxiao Wang, Huang-qin Song, Lei Zhang, Tao Li, Jiefeng He, and Haoliang Zhao. The functional mechanisms of toll-like receptor 3 and its implications in digestive system tumors. Frontiers in bioscience, 28 11:297, Nov 2023. URL: https://doi.org/10.31083/j.fbl2811297, doi:10.31083/j.fbl2811297. This article has 8 citations and is from a peer-reviewed journal.
(han2023thefunctionalmechanisms pages 3-5): Bin Han, Chao Zhang, Xiaoxiao Wang, Huang-qin Song, Lei Zhang, Tao Li, Jiefeng He, and Haoliang Zhao. The functional mechanisms of toll-like receptor 3 and its implications in digestive system tumors. Frontiers in bioscience, 28 11:297, Nov 2023. URL: https://doi.org/10.31083/j.fbl2811297, doi:10.31083/j.fbl2811297. This article has 8 citations and is from a peer-reviewed journal.
(ouattara2025tolllikereceptor3 pages 1-2): Abdoul Karim Ouattara, Issoufou Tao, Julien Dembélé, and Jacques Simpore. Toll-like receptor 3 in hepatitis b and c: a determinant of infection. Cellular and Molecular Biology, 71:81-93, Dec 2025. URL: https://doi.org/10.14715/cmb/2025.71.12.10, doi:10.14715/cmb/2025.71.12.10. This article has 0 citations.
(han2023thefunctionalmechanisms pages 2-3): Bin Han, Chao Zhang, Xiaoxiao Wang, Huang-qin Song, Lei Zhang, Tao Li, Jiefeng He, and Haoliang Zhao. The functional mechanisms of toll-like receptor 3 and its implications in digestive system tumors. Frontiers in bioscience, 28 11:297, Nov 2023. URL: https://doi.org/10.31083/j.fbl2811297, doi:10.31083/j.fbl2811297. This article has 8 citations and is from a peer-reviewed journal.
(luan2024innateimmuneresponses pages 5-7): Xiaohan Luan, Lei Wang, Guangji Song, and Wen Zhou. Innate immune responses to rna: sensing and signaling. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2024.1287940, doi:10.3389/fimmu.2024.1287940. This article has 102 citations and is from a peer-reviewed journal.
(sakaniwa2023tlr3formsa pages 1-2): Kentaro Sakaniwa, Akiko Fujimura, Takuma Shibata, Hideki Shigematsu, Toru Ekimoto, Masaki Yamamoto, Mitsunori Ikeguchi, Kensuke Miyake, Umeharu Ohto, and Toshiyuki Shimizu. Tlr3 forms a laterally aligned multimeric complex along double-stranded rna for efficient signal transduction. Nature Communications, Jan 2023. URL: https://doi.org/10.1038/s41467-023-35844-2, doi:10.1038/s41467-023-35844-2. This article has 75 citations and is from a highest quality peer-reviewed journal.
(sakaniwa2023tlr3formsa pages 3-4): Kentaro Sakaniwa, Akiko Fujimura, Takuma Shibata, Hideki Shigematsu, Toru Ekimoto, Masaki Yamamoto, Mitsunori Ikeguchi, Kensuke Miyake, Umeharu Ohto, and Toshiyuki Shimizu. Tlr3 forms a laterally aligned multimeric complex along double-stranded rna for efficient signal transduction. Nature Communications, Jan 2023. URL: https://doi.org/10.1038/s41467-023-35844-2, doi:10.1038/s41467-023-35844-2. This article has 75 citations and is from a highest quality peer-reviewed journal.
(ouattara2025tolllikereceptor3 pages 2-3): Abdoul Karim Ouattara, Issoufou Tao, Julien Dembélé, and Jacques Simpore. Toll-like receptor 3 in hepatitis b and c: a determinant of infection. Cellular and Molecular Biology, 71:81-93, Dec 2025. URL: https://doi.org/10.14715/cmb/2025.71.12.10, doi:10.14715/cmb/2025.71.12.10. This article has 0 citations.
(chai2025myd88contributesto pages 10-12): Zhuo-Dong Chai, Yu-Qi Zhou, Ling Yang, Yan Zhang, Sukria Hossain, Sahelosadat Hajimirzaei, Jiaqian Qi, Guo-Ying Zhang, Yi-Nan Wei, and Zhen-Yu Li. Myd88 contributes to tlr3-mediated nf-κb activation and cytokine production in macrophages. Cells, 14:1507, Sep 2025. URL: https://doi.org/10.3390/cells14191507, doi:10.3390/cells14191507. This article has 16 citations.
(shrestha2024differentialtlrerk12activity pages 5-7): Rakshya Shrestha, Paige Marie Johnson, Roshan Ghimire, Cody John Whitley, and Rudragouda Channappanavar. Differential tlr-erk1/2 activity promotes viral ssrna and dsrna mimic-induced dysregulated immunity in macrophages. Pathogens, 13:1033, Nov 2024. URL: https://doi.org/10.3390/pathogens13121033, doi:10.3390/pathogens13121033. This article has 2 citations.
(wang2025emergingrolesof pages 4-6): Dang Wang and Kui Li. Emerging roles of trim56 in antiviral innate immunity. Viruses, 17:72, Jan 2025. URL: https://doi.org/10.3390/v17010072, doi:10.3390/v17010072. This article has 9 citations.
(chai2025myd88contributesto pages 12-14): Zhuo-Dong Chai, Yu-Qi Zhou, Ling Yang, Yan Zhang, Sukria Hossain, Sahelosadat Hajimirzaei, Jiaqian Qi, Guo-Ying Zhang, Yi-Nan Wei, and Zhen-Yu Li. Myd88 contributes to tlr3-mediated nf-κb activation and cytokine production in macrophages. Cells, 14:1507, Sep 2025. URL: https://doi.org/10.3390/cells14191507, doi:10.3390/cells14191507. This article has 16 citations.
(liu2024keyrolesfor pages 11-12): Benjamin M. Liu, Nan L. Li, Ruixue Wang, Xiaofan Li, Z. Alex Li, Tony N. Marion, and Kui Li. Key roles for phosphorylation and the coiled-coil domain in trim56-mediated positive regulation of tlr3-trif–dependent innate immunity. Journal of Biological Chemistry, 300:107249, May 2024. URL: https://doi.org/10.1016/j.jbc.2024.107249, doi:10.1016/j.jbc.2024.107249. This article has 40 citations and is from a domain leading peer-reviewed journal.
(liu2024keyrolesfor pages 1-2): Benjamin M. Liu, Nan L. Li, Ruixue Wang, Xiaofan Li, Z. Alex Li, Tony N. Marion, and Kui Li. Key roles for phosphorylation and the coiled-coil domain in trim56-mediated positive regulation of tlr3-trif–dependent innate immunity. Journal of Biological Chemistry, 300:107249, May 2024. URL: https://doi.org/10.1016/j.jbc.2024.107249, doi:10.1016/j.jbc.2024.107249. This article has 40 citations and is from a domain leading peer-reviewed journal.
(manik2025structuralbasisfor pages 5-6): Mohammad K. Manik, Mengqi Pan, Le Xiao, Weixi Gu, Hyoyoung Kim, Sabrina Pospich, Andrew Hedger, Parimala R. Vajjhala, Morris Y. L. Lee, Xiaoqi Qian, Michael J. Landsberg, Thomas Ve, Jeffrey D. Nanson, Stefan Raunser, Katryn J. Stacey, Hao Wu, and Bostjan Kobe. Structural basis for tir domain–mediated innate immune signaling by toll-like receptor adaptors trif and tram. Proceedings of the National Academy of Sciences of the United States of America, Jan 2025. URL: https://doi.org/10.1073/pnas.2418988122, doi:10.1073/pnas.2418988122. This article has 22 citations and is from a highest quality peer-reviewed journal.
(hu2024trifdependentsignalingand pages 1-2): Lilin Hu, Zilu Cheng, Huikuan Chu, Weijun Wang, Yu Jin, and Ling Yang. Trif-dependent signaling and its role in liver diseases. Frontiers in Cell and Developmental Biology, Apr 2024. URL: https://doi.org/10.3389/fcell.2024.1370042, doi:10.3389/fcell.2024.1370042. This article has 42 citations.
(hu2024trifdependentsignalingand pages 3-5): Lilin Hu, Zilu Cheng, Huikuan Chu, Weijun Wang, Yu Jin, and Ling Yang. Trif-dependent signaling and its role in liver diseases. Frontiers in Cell and Developmental Biology, Apr 2024. URL: https://doi.org/10.3389/fcell.2024.1370042, doi:10.3389/fcell.2024.1370042. This article has 42 citations.
(hu2024trifdependentsignalingand pages 2-3): Lilin Hu, Zilu Cheng, Huikuan Chu, Weijun Wang, Yu Jin, and Ling Yang. Trif-dependent signaling and its role in liver diseases. Frontiers in Cell and Developmental Biology, Apr 2024. URL: https://doi.org/10.3389/fcell.2024.1370042, doi:10.3389/fcell.2024.1370042. This article has 42 citations.
(hu2024trifdependentsignalingand pages 5-6): Lilin Hu, Zilu Cheng, Huikuan Chu, Weijun Wang, Yu Jin, and Ling Yang. Trif-dependent signaling and its role in liver diseases. Frontiers in Cell and Developmental Biology, Apr 2024. URL: https://doi.org/10.3389/fcell.2024.1370042, doi:10.3389/fcell.2024.1370042. This article has 42 citations.
(butkowsky2023toll‑likereceptor3 pages 1-2): Carly Butkowsky, Natalie Aldor, and Sarah Poynter. Toll‑like receptor 3 ligands for breast cancer therapies (review). Molecular and Clinical Oncology, Jun 2023. URL: https://doi.org/10.3892/mco.2023.2656, doi:10.3892/mco.2023.2656. This article has 13 citations.
(hsieh2025tolllikereceptor3 pages 2-4): Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, and Razelle Kurzrock. Toll-like receptor 3: a double-edged sword. Biomarker Research, Feb 2025. URL: https://doi.org/10.1186/s40364-025-00739-5, doi:10.1186/s40364-025-00739-5. This article has 46 citations and is from a peer-reviewed journal.
(hsieh2025tolllikereceptor3 pages 4-6): Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, and Razelle Kurzrock. Toll-like receptor 3: a double-edged sword. Biomarker Research, Feb 2025. URL: https://doi.org/10.1186/s40364-025-00739-5, doi:10.1186/s40364-025-00739-5. This article has 46 citations and is from a peer-reviewed journal.
(hsieh2025tolllikereceptor3 pages 12-12): Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, and Razelle Kurzrock. Toll-like receptor 3: a double-edged sword. Biomarker Research, Feb 2025. URL: https://doi.org/10.1186/s40364-025-00739-5, doi:10.1186/s40364-025-00739-5. This article has 46 citations and is from a peer-reviewed journal.
(chai2025myd88contributesto pages 17-17): Zhuo-Dong Chai, Yu-Qi Zhou, Ling Yang, Yan Zhang, Sukria Hossain, Sahelosadat Hajimirzaei, Jiaqian Qi, Guo-Ying Zhang, Yi-Nan Wei, and Zhen-Yu Li. Myd88 contributes to tlr3-mediated nf-κb activation and cytokine production in macrophages. Cells, 14:1507, Sep 2025. URL: https://doi.org/10.3390/cells14191507, doi:10.3390/cells14191507. This article has 16 citations.
(han2023thefunctionalmechanisms pages 6-7): Bin Han, Chao Zhang, Xiaoxiao Wang, Huang-qin Song, Lei Zhang, Tao Li, Jiefeng He, and Haoliang Zhao. The functional mechanisms of toll-like receptor 3 and its implications in digestive system tumors. Frontiers in bioscience, 28 11:297, Nov 2023. URL: https://doi.org/10.31083/j.fbl2811297, doi:10.31083/j.fbl2811297. This article has 8 citations and is from a peer-reviewed journal.
(hsieh2025tolllikereceptor3 pages 7-9): Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, and Razelle Kurzrock. Toll-like receptor 3: a double-edged sword. Biomarker Research, Feb 2025. URL: https://doi.org/10.1186/s40364-025-00739-5, doi:10.1186/s40364-025-00739-5. This article has 46 citations and is from a peer-reviewed journal.
(hsieh2025tolllikereceptor3 pages 9-10): Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, and Razelle Kurzrock. Toll-like receptor 3: a double-edged sword. Biomarker Research, Feb 2025. URL: https://doi.org/10.1186/s40364-025-00739-5, doi:10.1186/s40364-025-00739-5. This article has 46 citations and is from a peer-reviewed journal.